Cerus Q3 2026: Breakeven EPS and a Phase 3 Red Blood Cell Win

As seen on the 24/7 Wall St. homepage on November 2, 2026.

CERS Cerus
Q3 2026
EPS
$0.00
est -$0.01 +100.0%
Revenue
$64M
est $61M +4.8%

Cerus broke even on the bottom line, beating expectations, as INTERCEPT Fibrinogen Complex volumes grew roughly 80%. Positive topline Phase 3 RedeS data for the red blood cell system landed the same day, pushing a much larger market within regulatory reach.

Continue ReadingShow less

Cerus reported Q3 2026 revenue of $64 million, up 21% year over year and beating expectations, and broke even on the bottom line against an estimated loss.

The primary revenue engine was INTERCEPT Fibrinogen Complex, where kit and finished-dose volumes grew roughly 80%, lifting U.S. IFC product sales and the North America segment.

The bigger catalyst landed alongside the financials: positive topline results from the Phase 3 RedeS trial for the INTERCEPT red blood cell system. Red cell transfusions represent a substantially larger addressable market than platelets or fibrinogen, and a successful regulatory submission would extend pathogen reduction technology to that population for the first time.

Sponsored

Management reiterated full-year 2026 product revenue guidance of $229 million to $231 million and guided IFC revenue of $23 million to $25 million. CEO Vivek Jayaraman said the Q3 result increases confidence heading into year-end.

International platelet kit volumes declined 3%, government contract revenue fell as legacy BARDA and FDA contracts wind down, and gross margin faced pressure from a weaker U.S. dollar against the euro and rising product costs. The FDA's review of the INT200 illuminator PMA remains ongoing, adding regulatory timing uncertainty.

Mentioned: CERS